CASI Pharmaceuticals

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Retrieved on: 
Monday, April 8, 2024
CASI, Therapy, Cayman, CASI Pharmaceuticals, Form 6-K

BEIJING, April 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas.

Key Points: 
  • BEIJING, April 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas.
  • For details, please visit below link:

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Retrieved on: 
Thursday, March 28, 2024
Agreement, Transplant, CASI Pharmaceuticals, CASI, Patient, Travel, PTCL, Immunoglobulin G, CMC, Depreciation, Bone marrow, Therapy, VCP, Marketing, Research, Cleave, Pralatrexate, MCL, Rituximab, AML, Pembrolizumab, Trial of the century, Myelodysplastic syndrome, Melphalan, MDS, Clinical trial, Follicular lymphoma, Republic, Multiple myeloma, Acute myeloid leukemia, Annual report, National Medical Products Administration, Haematopoietic system, FDA, Cayman, CD19, NMPA, COVID-19, CTA, HKIAC, NHL, Non-Hodgkin lymphoma, MICL, Pharmaceutical industry

BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.

Key Points: 
  • BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
  • CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA®, 33% lower than the same period in 2022.
  • 2023 marks a major milestone for CASI and our partner Juventas; Inaticabtagene Autoleucel (CNCT-19 CAR-T cell therapy) was approved by National Medical Products Administration (NMPA) in November 2023.
  • As of December 31, 2023, CASI had cash, cash equivalents and short term investment of $29.1 million compared to $48.6 million as of December 31, 2022.

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Retrieved on: 
Tuesday, November 14, 2023
Acquisition, Research, National Medical Products Administration, CASI, Investment, CASI Pharmaceuticals, NMPA, Cell, Marketing, Therapy, B-ALL, Acute lymphoblastic leukemia, Melphalan, Pharmaceutical industry, Cryptocurrency, Juventas

BEIJING, Nov. 14, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • BEIJING, Nov. 14, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the third quarter ended September 30, 2023.
  • He further added, "Our sales revenue for the third quarter of 2023 was $8.8 million, representing a decrease of 13.5% compared to the same period last year and a decrease of 10% from the second quarter of 2023.
  • Revenue was $8.8 million for the three months ended September 30, 2023, compared to $10.2 million for the three months ended September 30, 2022.
  • As of September 30, 2023, CASI had cash, cash equivalents and short-term investments of $34.2 million.

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Retrieved on: 
Friday, August 11, 2023
Rituximab, Travel, Therapy, Marketing, CASI, New Drug Application, NDA, Juventas, CASI Pharmaceuticals, Patient, Investment, National Medical Products Administration, Research, NMPA, Pharmaceutical industry, Cryptocurrency

BEIJING, Aug. 11, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the quarter ended June 30, 2023.

Key Points: 
  • BEIJING, Aug. 11, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the quarter ended June 30, 2023.
  • Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $9.8 million sales revenue for the second quarter of 2023.
  • This is a 15% increase compared to the same period last year and an 18% of increase from the first quarter of 2023."
  • As of June 30, 2023, CASI had cash, cash equivalents and short-term investments of $36.8 million.

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

Retrieved on: 
Tuesday, August 1, 2023
Agreement, PTCL, US Foods, Therapy, Doctor of Philosophy, Assignment, CASI, MICL, Medicine, CASI Pharmaceuticals, Republic, Patient, National Medical Products Administration, FDA, Pralatrexate, Good, Food, NMPA, Generic drug, Pharmaceutical industry

FOLOTYN® (Pralatrexate) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ("PTCL").

Key Points: 
  • FOLOTYN® (Pralatrexate) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ("PTCL").
  • This product was approved by both the US Food and Drug Administration ("FDA") and China's National Medical Products Administration (NMPA) for PTCL.
  • Under the terms of the Agreement, CASI will assume MICL's rights and obligations with respect to the commercialization of FOLOTYN® in China.
  • We look forward to this exciting launch and bringing this novel medicine to PTCL patients in China," said Dr. Ashish Anvekar, President of Acrotech Biopharma.

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Retrieved on: 
Thursday, July 20, 2023
Myelodysplastic syndrome, DNA, Cleave, Therapy, Assignment, CASI, CASI Pharmaceuticals, Acute myeloid leukemia, MDS, Malignancy, AML, Investigational New Drug, Patient, Good, VCP, Pharmaceutical industry

BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product.

Key Points: 
  • BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product.
  • Additionally, CASI will assume responsibility of the United States ("US") CB-5339 Investigational New Drug ("IND") application.
  • CB-5339 is an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, designed to disrupt protein homeostasis, DNA damage response and other cellular stress pathways.
  • We are encouraged by the early clinical data in the phase 1 study of CB-5339 in patients with AML and MDS.

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

Retrieved on: 
Thursday, July 20, 2023
Oncology, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Myelodysplastic syndrome, DNA, Therapy, ATPase, CASI, Multiple myeloma, Cancer, Doctor of Philosophy, CASI Pharmaceuticals, Science, Acute myeloid leukemia, Clinical trial, AAA, MD, Patient, Engineering, Melphalan, VCP, Bone marrow, Fine chemical, Pharmaceutical industry, Cleave, Eikon

Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global rights to the company’s clinical asset, CB-5339, and Eikon Therapeutics has acquired rights to the company’s pre-clinical assets.

Key Points: 
  • Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global rights to the company’s clinical asset, CB-5339, and Eikon Therapeutics has acquired rights to the company’s pre-clinical assets.
  • Eikon Therapeutics is a clinical-stage company working to advance breakthrough therapeutics through the purposeful integration of engineering and science.
  • “Both CASI and Eikon have unique capabilities and the expertise to continue advancing Cleave programs for patients with unmet needs in cancer and other indications,” said Amy Burroughs, president and chief executive officer of Cleave Therapeutics.
  • “The robust scientific and clinical insights the Cleave team has generated over the past decade will inform future development across multiple novel targets and disease areas.

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

Retrieved on: 
Wednesday, April 26, 2023
Annual report, Therapy, Bank statement, CASI Pharmaceuticals, CASI, Cryptocurrency

BEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission ("SEC") on April 26, 2023.

Key Points: 
  • BEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission ("SEC") on April 26, 2023.
  • The annual report can be accessed on the Company's investor relations website at https://www.casipharmaceuticals.com/investor-relations/ as well as the SEC's website at https://www.sec.gov/ .
  • The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request.
  • Requests should be directed to Investor Relations Department, CASI Pharmaceuticals, Inc., Rm 1701-1702, China Central Office Tower 1, No.81 Jianguo Road Chaoyang District, Beijing, 100025, China.

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

Retrieved on: 
Wednesday, April 26, 2023
Cayman, CD19, Marketing, Breakthrough therapy, Patient, Immunoglobulin G, National Medical Products Administration, MM, Bone marrow, Therapy, Multiple myeloma, CASI Pharmaceuticals, FDA, IND, NMPA, Safety, ALL, ODD, CASI, Non-Hodgkin lymphoma, COVID-19, Acute lymphoblastic leukemia, Haematopoietic system, Acute myeloid leukemia, B-ALL, Annual report, Research, Pembrolizumab, VCP, Myelodysplastic syndrome, Rituximab, Follicular lymphoma, Center for Drug Evaluation and Research, NDA, NHL, CTA, MDS, AML, Clinical trial, City, MCL, Transplant, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, Juventas

BEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022.

Key Points: 
  • BEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022.
  • Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $10.2 million in EVOMELA® revenues for the fourth quarter, $38 million for the full-year 2022.
  • 2022 marks a major milestone for CASI and our partner Juventas; the CNCT-19 New Drug Application (NDA) was accepted by National Medical Products Administration (NMPA) in December 2022.
  • As of December 31, 2022, CASI had cash and cash equivalents of $47.1 million compared to $38.7 million as of December 31, 2021.

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Retrieved on: 
Tuesday, March 21, 2023
Therapy, CASI Pharmaceuticals, CASI, Generic drug, Security (finance), Financial services

BEIJING, March 21, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that the redomiciliation merger to redomicile the Company as a Cayman Islands company (the "Redomiciliation Merger") has been completed.

Key Points: 
  • BEIJING, March 21, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that the redomiciliation merger to redomicile the Company as a Cayman Islands company (the "Redomiciliation Merger") has been completed.
  • Pursuant to the Redomiciliation Merger, each outstanding share of the common stock of the Company was converted into the right to receive one ordinary share of CASI Pharmaceuticals, Inc., a company incorporated under the laws of the Cayman Islands ("CASI Cayman").
  • The ordinary shares of CASI Cayman will be listed on the NASDAQ Capital Market under the trading symbol "CASI," the same symbol under which the common stock of the Company was listed.